Table 4.
Top 10 most highly expressed genes in the “late” phase (24 hours) of induction resulting from treatment with a 200-nM dose of CDDO-Im in HUVEC.
| Symbol | Name | 0.5 h | 1 h | 3 h | 6 h | 24 h |
|---|---|---|---|---|---|---|
| GPIHBP1 | Glycosylphosphatidylinositol anchored high-density lipoprotein–binding protein 1 | 1.6 | 2.1 | 1.8 | 1.5 | 12.6 |
| CXCR4 | Chemokine (C-X-C motif) receptor 4 | 1.8 | 1.1 | 0.5 | 0.9 | 12.0 |
| MAN1C1 | Mannosidase, alpha, class 1C, member 1 | 4.9 | 5.4 | 4.0 | 1.1 | 9.8 |
| TFEC | Transcription factor EC | 1.7 | 0.8 | 1.7 | 3.4 | 7.1 |
| FLJ34503 | Uncharacterized FLJ34503 | 3.5 | 2.6 | 1.7 | 1.0 | 6.7 |
| AFAP1L2 | Actin filament–associated protein 1-like 2 | 5.1 | 4.9 | 2.6 | 1.6 | 6.6 |
| TIMP3 | TIMP metallopeptidase inhibitor 3 | 4.8 | 5.0 | 3.7 | 1.1 | 6.2 |
| SEMA6A | Sema domain, transmembrane domain (TM), and cytoplasmic domain, semaphorin 6A | 5.3 | 1.6 | 0.7 | 0.7 | 5.9 |
| INHBB | Inhibin, beta B | 7.7 | 9.0 | 2.0 | 0.7 | 5.9 |
| APCDD1 | Adenomatous polyposis coli downregulated 1 | 1.6 | 1.9 | 0.8 | 0.6 | 5.4 |
Abbreviations: CDDO-Im, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; HUVEC, human umbilical vein endothelial cells.
Values at each time point represent fold change compared with control (dimethyl sulfoxide vehicle–treated HUVEC at time 0) after normalization to housekeeping genes.